GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK and Oxford researchers to create cancer vaccine to stop disease developing - GSK will invest up to £50 million in the new ...

A programme looking to advance the understanding of how cancer develops has been backed with £50 million. Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford ...

Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...

GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

A new cancer vaccine is being created to analyse how pre-cancerous cells develop to target the disease before it takes hold.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers could be prevented from developing with jabs.

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...

GSK plc and the University of Oxford (Oxford) announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...